Corpus Intelligence IC Memo — ADVENTHEALTH TAMPA 2026-04-26 04:01 UTC
IC Memo — ADVENTHEALTH TAMPA
Investment Committee Memorandum | FL | 596 beds | Grade C | EBITDA uplift $51.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ADVENTHEALTH TAMPA

CCN 100173 | HILLSBOROUGH, FL | 596 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ADVENTHEALTH TAMPA is a 596-bed suburban community hospital in HILLSBOROUGH, FL with $699.2M in net patient revenue and a -8.5% operating margin. The hospital serves a payer mix of 19.7% Medicare, 9.8% Medicaid, and 70.5% commercial.

Thesis: Undervalued. Our ML models identify $51.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -8.5% to -1.2% (+736bps).

Net Revenue HCRIS$699.2M
Current EBITDA COMPUTED$-59.6M
Operating Margin COMPUTED-8.5%
Occupancy HCRIS60.9%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS17.3%
Distress Probability ML47.0%

2. Market Context & Competitive Position

261
FL Hospitals
3.2%
State Median Margin
54
Comparable Hospitals

FL has 261 Medicare-certified hospitals with a median operating margin of 3.2%. The target's margin of -8.5% places it below the state median. Among 54 size-comparable peers (298-1192 beds), the median margin is 6.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (298-1192), prioritizing same-state peers. 54 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ADVENTHEALTH TAMPA (Target)FL596$699.2M-8.5%
UNIVERSITY OF MIAMI HOSP & CLIFL532$2.36B0.9%
UF HEALTH SHANDSFL994$2.24B10.4%
BAPTIST MEDICAL CENTERFL980$1.78B0.9%
TAMPA GENERAL HOSPITALFL898$1.73B-9.3%
BAPTIST HOSPITALFL948$1.71B10.8%
MEMORIAL REGIONAL HOSPITALFL838$1.45B-20.7%
LEE MEMORIAL HOSPITALFL748$1.28B17.4%
SARASOTA MEMORIAL HOSPITALFL787$1.10B8.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $51.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$14.7M+210bp18mo
Cost to Collect4.5%2.5%$14.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$13.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$8.5M+122bp9mo
Clean Claim Rate88.0%96.0%$447K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$14.7M
Cost to Collect
$14.0M
Denial Rate Reduction
$13.8M
A/R Days Reduction
$8.5M
Clean Claim Rate
$447K
Total EBITDA Uplift$51.5M
Current EBITDA$-59.6M
+ RCM Uplift+$51.5M
Pro Forma EBITDA$-8.2M
Current Margin-8.5%
Pro Forma Margin-1.2%
WC Released (1x)$26.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-91.7M$121.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-91.7M$103.7M0.00x-100.0%
Bull Case9.0x11.0x$-82.6M$243.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-82.6M$241.5M0.00x-100.0%
Bear Case11.0x10.0x$-100.9M$-106.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-100.9M$-149.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 54 hospitals with 298-1192 beds
  • Same-state prioritization (n=55)
  • Comp margins: P25=-6.9% / P50=6.2% / P75=15.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.